Epigenetics-targeted drugs: current paradigms and future challenges
Open accessThe DOI matches its Crossref record; 1,077 of the 1,077 references it cites were found in a registry or an index.
Abstract
Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifying enzymes in pathological conditions. Over the past two decades, a growing array of small molecule drugs targeting epigenetic enzymes such as DNA methyltransferase, histone deacetylase, isocitrate dehydrogenase, and enhancer of zeste homolog 2, have been thoroughly investigated and implemented as therapeutic options, particularly in oncology. Additionally, numerous epigenetics-targeted drugs are undergoing clinical trials, offering promising prospects for clinical benefits. This review delineates the roles of epigenetics in physiological and pathological contexts and underscores pioneering studies on the discovery and clinical implementation of epigenetics-targeted drugs. These include inhibitors, agonists, degraders, and multitarget agents, aiming to identify practical challenges and promising avenues for future research. Ultimately, this review aims to deepen the understanding of epigenetics-oriented therapeutic strategies and their further application in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–800 of 1,077
Evanno, E., Godet, J., Piccirilli, N., Guilhot, J., Milin, S., Gombert, J. M., Fouchaq, B., & Roche, J. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0380-0 · Cited by 57
Grivas, P. D., Mortazavi, A., Picus, J., Hahn, N. M., Milowsky, M. I., Hart, L. L., Alva, A. S., Joaquim Bellmunt, B., Pal, S. K., Bambury, R. M., et al. (2018) · Cancer · doi:10.1002/cncr.31817 · Cited by 57
A unique histone 3 lysine 14 chromatin signature underlies tissue-specific gene regulation
Regadas, I., Dahlberg, O., Vaid, R., Ho, O. M., Belikov, S. V., Dixit, G., Deindl, S., Wen, J., & Mannervik, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.041 · Cited by 57
Cui, Y., Wu, Y., Wang, C., Wang, Z., Li, Y., Jiang, Z., Zhao, W., & Pan, Z. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154299 · Cited by 57
Itzykson, R., Santini, V., Thépot, S., Adès, L., Chaffaut, C., Giagounidis, A. A. N., Morabito, M., Droin, N. M., Lübbert, M., Sapena, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00437 · Cited by 57
Brunetto, A. T., Ang, J. E., Lal, R., Olmos, D., Molife, L. R., Kristeleit, R. S., Parker, A., Casamayor, I., Olaleye, M., Mais, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0735 · Cited by 56
Igoe, N., Bayle, E. D., Fedorov, O., Tallant, C., Savitsky, P. A., Rogers, C. M., Owen, D. R., Deb, G., Somervaille, T. C. P., Andrews, D. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01583 · Cited by 56
Huang, J., Tian, R., Yang, Y., Jiang, R., Dai, J., Tang, L. P., & Zhang, L. (2017) · Innate Immunity · doi:10.1177/1753425917733531 · Cited by 56
Sébert, M., Renneville, A., Bally, C., Péterlin, P., Beyne‐Rauzy, O., Legros, L., Gourin, M.-P., Sanhès, L., Wattel, E., Gyan, E., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207118 · Cited by 56
Givinostat: an emerging treatment for polycythemia vera
Chifotides, H. T., Bose, P., & Verstovšek, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1761323 · Cited by 56
Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers
Liu, Y., Guo, B., Aguilera-Jimenez, E., Chu, V. S., Zhou, J. R., Wu, Z., Francis, J. M., Yang, X., Choi, P. S., Bailey, S. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1287 · Cited by 56
Saha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Landsburg, D. J., Barta, S. K., Ramchandren, R., Batlevi, C. L., Iyer, S. P., Kelly, K. R., Micallef, I. N., Smith, S. M., Stevens, D. A., Alvarez, M. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17730 · Cited by 56
Structural Basis of Sirtuin 6-Catalyzed Nucleosome Deacetylation
Wang, Z. A., Markert, J. W., Whedon, S. D., Abeywardana, M. Y., Lee, K., Jiang, H., Suarez, C., Lin, H., Farnung, L., & Cole, P. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13512 · Cited by 56
Zhang, Y., Deng, Q., Hong, H., Qian, Z., Wan, B., & Xia, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05089-8 · Cited by 56
Byun, H., Choi, S. H., Laird, P. W., Trinh, B., Siddiqui, M. A., Márquez, V. E., & Yang, A. S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.069 · Cited by 55
Nemunaitis, J. J., Orr, D. W., Eager, R., Cunningham, C. C., Williams, A., Mennel, R. G., Grove, W. R., & Olson, S. C. (2003) · The Cancer Journal · doi:10.1097/00130404-200301000-00010 · Cited by 55
Liang, J., Zhang, B., Labadie, S. S., Ortwine, D. F., Vinogradova, M. V., Kiefer, J. R., Gehling, V. S., Harmange, J.-C., Cummings, R. T., Lai, T., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.06.078 · Cited by 55
UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP
Jiao, D., Huan, Y., Zheng, J., Wei, M., Zheng, G., Han, D., Wu, J., Xi, W., Wei, F., Yang, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0822-6 · Cited by 55
Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems
Zhang, M., Xu, N., Xu, W., Ling, G., & Zhang, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105861 · Cited by 55
Issa, J. J., Kantarjian, H. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1726 · Cited by 55
Selberg, S., Yu, L.-Y., Bondarenko, O. M., Kankuri, E. M., Seli, N., Kovaleva, V. D., Herodes, K., Saarma, M., & Karelson, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094537 · Cited by 54
Haverkos, B. M., Alpdoğan, Ö., Baiocchi, R. A., Brammer, J. E., Feldman, T. A., Capra, M., Brem, E. A., Nair, S. M., Scheinberg, P., Pereira, J. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010330 · Cited by 54
Li, Y., Sui, S., & Goel, A. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.02.001 · Cited by 54
Qiu, Y., Zhang, W., Zhao, C., Wang, Y., Wang, W., Zhang, J., Zhang, Z., Li, G., Shi, Y., Tu, X., et al. (2011) · Biochemical Journal · doi:10.1042/bj20111885 · Cited by 53
KDM6B (JMJD3) and its dual role in cancer
Lagunas‐Rangel, F. A. (2021) · Biochimie · doi:10.1016/j.biochi.2021.02.005 · Cited by 53
Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington’s disease mice
Pupak, A., Singh, A., Sancho‐Balsells, A., Alcalá‐Vida, R., Espina, M., Giralt, A., Martí, E., Ørom, U. A., Ginés, S., & Brito, V. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04444-6 · Cited by 53
Pant, R., Kabeer, S. W., Sharma, S., Kumar, V., Patra, D., Pal, D., & Tikoo, K. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104779 · Cited by 53
Wei, C., Ya, X., Shen, Q., Li, R., Xiao, X., Saw, P. E., & Xu, X. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.009 · Cited by 53
Self-citationA covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO
Lai, G., Li, Y., Zhu, H., Zhang, T., Gao, J., Zhou, H., & Yang, C. (2024) · RSC Chemical Biology · doi:10.1039/d3cb00230f · Cited by 53
Chu, Q., Nielsen, T. O., Alcindor, T., Gupta, A. A., Endo, M., Goytain, A., Xu, H., Verma, S., Tozer, R. G., Knowling, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv033 · Cited by 52
Foss, F. M., Horwitz, S. M., Pro, B., Prince, H. M., Sokol, L., Balser, B., Wolfson, J., & Coiffier, B. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0243-8 · Cited by 52
Rago, F., Rodrigues, L. U., Bonney, M., Sprouffske, K., Kurth, E., Elliott, G., Ambrose, J., Aspesi, P., Oborski, J., Chen, J. T., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0390 · Cited by 52
Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties
Xiao, P., Duan, Z., Liu, Z., Chen, L., Zhang, D., Liu, L., Zhou, C., Gan, J., Dong, Z., & Yang, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00543 · Cited by 52
Xu, R. F., Huang, L., Liu, J., Zhang, Y., Xu, Y., Li, R., Su, S., & Xu, X. (2023) · Small · doi:10.1002/smll.202305923 · Cited by 52
Ngamphaiboon, N., Dy, G. K., Ma, W. W., Zhao, Y., Reungwetwattana, T., DePaolo, D., Ding, Y., Brady, W. E., Fetterly, G. J., & Adjei, A. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0174-6 · Cited by 51
Welch, J. S., Klco, J. M., Gao, F., Procknow, E., Uy, G. L., Stockerl‐Goldstein, K. E., Abboud, C. N., Westervelt, P., DiPersio, J. F., Hassan, A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22092 · Cited by 51
Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain
Senisterra, G. A., Zhu, H. Y. H., Luo, X., Zhang, H., Xun, G., Lu, C., Xiao, W., Hajian, T., Loppnau, P., Chau, I., et al. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218766278 · Cited by 51
Tak, W. Y., Ryoo, B., Lim, H. Y., Kim, D. Y., Okusaka, T., Ikeda, M., Hidaka, H., Yeon, J.-E., Mizukoshi, E., Morimoto, M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0658-x · Cited by 51
Zhang, Y., Zhou, L., Safran, H. P., Borsuk, R., Lulla, R. R., Tapinos, N., Seyhan, A. A., & El‐Deiry, W. S. (2021) · Neoplasia · doi:10.1016/j.neo.2021.06.007 · Cited by 51
Current Treatment of Juvenile Myelomonocytic Leukemia
Mayerhofer, C., Niemeyer, C. M., & Flotho, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143084 · Cited by 51
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Ahmed, N. S., Gatchalian, J., Ho, J., Burns, M. J., Hah, N., Wei, Z., Downes, M., Evans, R. M., & Hargreaves, D. C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110812119 · Cited by 51
The IL‐21‐TET2‐AIM2‐c‐MAF pathway drives the T follicular helper cell response in lupus‐like disease
Wu, H., Deng, Y., Long, D., Yang, M., Li, Q., Feng, Y., Chen, Y., Qiu, H. X., Huang, X., He, Z., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.781 · Cited by 51
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 51
Pomaville, M. M., Chennakesavalu, M., Wang, P., Jiang, Z., Sun, H., Ren, P., Borchert, R., Gupta, V., Ye, C., Ge, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114165 · Cited by 51
Siebel, A. L., Trinh, S. K., Formosa, M. F., Mundra, P. A., Natoli, A. K., Reddy-Luthmoodoo, M., Huynh, K., Khan, A. A., Carey, A. L., van Hall, G., et al. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.002 · Cited by 50
von Tresckow, B., Sayehli, C., Aulitzky, W. E., Goebeler, M., Schwab, M., Braz, E., Krauss, B., Krauss, R., Hermann, F., Bartz, R., et al. (2019) · European Journal of Haematology · doi:10.1111/ejh.13188 · Cited by 50
Hollebecque, A., Salvagni, S., Plummer, R., Isambert, N., Niccoli, P., Capdevila, J., Curigliano, G., Moreno, V., Martín-Romano, P., Baudin, É., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2380 · Cited by 50
Luo, D., Li, W., Xie, C., Yin, L., Su, X., Chen, J., & Huang, H. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18778 · Cited by 50
Song, Y., Liu, Y., Li, Z., Li, L., Su, H., Jin, Z., Zuo, X., Wu, J., Zhou, H., Li, K., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00134-x · Cited by 50
Noviello, T., Giacomo, A. M. D., Caruso, F. P., Covre, A., Mortarini, R., Scala, G., Costa, M. C., Coral, S., Fridman, W. H., Sautès‐Fridman, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40994-4 · Cited by 50
Fiskus, W. C., Piel, J. C., Collins, M. P., Hentemann, M., Cuglievan, B., Mill, C. P., Birdwell, C. E., Das, K., Davis, J. A., Hou, H., et al. (2024) · Blood · doi:10.1182/blood.2023022832 · Cited by 50
Xu, Y., Yang, Y., Wang, Z., Sjöström, M., Jiang, Y., Tang, Y., Cheng, S., Deng, S., Wang, C., Gonzalez, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0539 · Cited by 50
Self-citationDiscovery of a Highly Selective Cell‐Active Inhibitor of the Histone Lysine Demethylases KDM2/7
Gerken, P. A., Wolstenhulme, J. R., Tumber, A., Hatch, S. B., Zhang, Y., Müller, S., Chandler, S. A., Mair, B., Li, F., Nijman, S. M. B., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706788 · Cited by 49
Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells
Xu, X., Wang, L., Hu, L., Dirks, W. G., Zhao, Y., Wei, Z., Chen, D., Li, Z., Wang, Z., Han, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32552 · Cited by 49
Chen, H., Jia, B., Zhang, Q., & Zhang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.870636 · Cited by 49
Liu, Z., Duan, Z., Zhang, D., Xiao, P., Zhang, T., Xu, H., Wang, C.-H., Rao, G.-W., Gan, J., Huang, Y., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00848 · Cited by 49
N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer’s disease
Jörg, M., Plehn, J. E., Kristen, M., Lander, M., Walz, L., Lietz, C., Wijns, J., Pichot, F., Rojas-Charry, L., Martin, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02421-y · Cited by 49
Mascarenhas, J. O., Sandy, L., Lü, M., Yoon, J., Petersen, B. E., Zhang, D., Ye, F., Newsom, C., Najfeld, V., Hochman, T., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.11.015 · Cited by 48
Baba, R., Matsuda, S., Arakawa, Y., Yamada, R. X., Suzuki, N., Ando, T., Oki, H., Igaki, S., Daini, M., Hattori, Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.aba1187 · Cited by 48
Position 34 of tRNA is a discriminative element for m5C38 modification by human DNMT2
Huang, Z., Li, J., Xiong, Q., Li, H., Wang, E., & Liu, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1148 · Cited by 48
Assi, R., Cherifi, C., Cornelis, F. M. F., Zhou, Q., Storms, L., Pazmiño, S., de Almeida, R. C., Meulenbelt, I., Lories, R. J. U., & Monteagudo, S. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223789 · Cited by 48
Ossenkoppele, G. J., Lowenberg, B., Zachee, P., Vey, N., Breems, D., Van de Loosdrecht, A. A., Davidson, A. H., Wells, G., Needham, L., Bawden, L., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12359 · Cited by 47
Tarhonskaya, H., Nowak, R. P., Johansson, C., Szykowska, A., Tumber, A., Hancock, R. L., Lang, P. A., Flashman, E., Oppermann, U. C. T., Schofield, C. J., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.007 · Cited by 47
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction
Du, D., Xu, D., Zhu, L., Stazi, G., Zwergel, C., Liu, Y., Luo, Z., Li, Y., Zhang, Y., Zhu, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02261 · Cited by 47
Mitochondrial dysfunction–induced H3K27 hyperacetylation perturbs enhancers in Parkinson’s disease
Huang, M., Lou, D. W., Charli, A., Kong, D., Jin, H., Zenitsky, G. D., Anantharam, V., Kanthasamy, A., Wang, Z., & Kanthasamy, A. G. (2021) · JCI Insight · doi:10.1172/jci.insight.138088 · Cited by 47
Wang, Y., Zhang, M., Song, W., Cai, Q., Zhang, L., Sun, X., Zou, L., Zhang, H., Wang, L., & Xue, H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26499 · Cited by 47
Wang, J.-J., Chen, D.-X., Zhang, Y., Xu, X., Cai, Y., Wei, W., Hao, J., & Wang, M. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00429-8 · Cited by 47
Montano, E. N., Bose, M., Huo, L., Tumurkhuu, G., Santos, G. D. L., Simental, B., Stotland, A. B., Wei, J., Merz, C. N. B., Suda, J., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42724 · Cited by 47
Chan, E. W., Chiorean, E. G., O'Dwyer, P. J., Gabrail, N. Y., Alcindor, T., Potvin, D., Chao, R. C., & Hurwitz, H. I. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3494-3 · Cited by 46
Kulikowski, E., Halliday, C., Johansson, J., Sweeney, M., Lebioda, K. E., Wong, N. C. W., Haarhaus, M. L., Brandenburg, V. M., Beddhu, S., Tonelli, M. A., et al. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000488257 · Cited by 46
GAS41 Recognizes Diacetylated Histone H3 through a Bivalent Binding Mode
Cho, H. J., Li, H., Linhares, B. M., Kim, E., Ndoj, J., Miao, H. Z., Grembecka, J. E., & Cierpicki, T. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00674 · Cited by 46
van Tilburg, C. M., Witt, R., Heiss, M., Pajtler, K. W., Plass, C., Poschke, I. C., Platten, M., Harting, I., Sedlaczek, O., Freitag, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07008-8 · Cited by 46
Alford, J. S., Lampe, J. W., Brach, D., Chesworth, R., Cosmopoulos, K., Duncan, K. W., Eckley, S. T., Kutok, J. L., Raimondi, A., Riera, T. V., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00167 · Cited by 46
Wang, Z., Wu, Q., Wang, H., Gao, Y., Nie, K., Tang, Y., Su, H., Hu, M., Gong, J., Fang, K., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154276 · Cited by 46
Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors
Granieri, L., Marocchi, F., Melixetian, M. B., Mohammadi, N., Nicoli, P., Cuomo, A., Bonaldi, T., Confalonieri, S., Pisati, F., Giardina, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111396 · Cited by 46
Wu, S., Lu, D., Gajendran, B., Hu, Q., Zhang, J., Wang, S., Han, M., Xu, Y., & Shen, X. (2023) · Phytotherapy Research · doi:10.1002/ptr.7831 · Cited by 46
Crawford, T. D., Vartanian, S., Côté, A., Bellon, S. F., Duplessis, M., Flynn, E. M., Hewitt, M. C., Huang, H.-R., Kiefer, J. R., Murray, J. M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.063 · Cited by 45
Zhang, W., Cheng, J., Diao, P., Wang, D., Zhang, W., Jiang, H., & Wang, Y. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0680-6 · Cited by 45
Selective Targeting of AF9 YEATS Domain by Cyclopeptide Inhibitors with Preorganized Conformation
Jiang, Y., Chen, G., Li, X., Liu, S., Tian, G., Li, Y., Li, X., Li, H., & Li, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10324 · Cited by 45
Self-citationEmerging role of G9a in cancer stemness and promises as a therapeutic target
Haebe, J. R., Bergin, C. J., Sandouka, T., & Benoit, Y. D. (2021) · Oncogenesis · doi:10.1038/s41389-021-00370-7 · Cited by 45
Blum, K. A., Supko, J. G., Maris, M. B., Flinn, I. W., Goy, A. H., Younes, A., Bobba, S., Senderowicz, A. M., Efuni, S., Rippley, R. K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0060 · Cited by 45
Short, N. J., & Kantarjian, H. M. (2022) · American Journal of Hematology · doi:10.1002/ajh.26667 · Cited by 45
Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia
Hu, C.-L., Chen, B., Li, Z., Yang, T., Xu, C., Yang, R., Yu, P., Zhao, J., Liu, T., Liu, N., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00735-6 · Cited by 45
Self-citationJang, H. J., Hostetter, G. H., Macfarlane, A. W., Madaj, Z., Ross, E. A., Hinoue, T., Kulchycki, J. R., Burgos, R. S., Tafseer, M., Alpaugh, R. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3642 · Cited by 45
Epigenome-wide association studies of allergic disease and the environment
Cárdenas, A., Fadadu, R. P., & Koppelman, G. H. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.05.020 · Cited by 45
SIRT7: a novel molecular target for personalized cancer treatment?
Ianni, A., Kumari, P., Tarighi, S., Braun, T. W., & Vaquero, A. (2024) · Oncogene · doi:10.1038/s41388-024-02976-8 · Cited by 45
Inhibition of METTL3 in macrophages provides protection against intestinal inflammation
Yin, H., Ju, Z., Zhang, X., Zuo, W., Yang, Y., Zheng, M., Zhang, X., Liu, Y., Peng, Y., Xing, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01156-8 · Cited by 45
Poziello, A., Nebbioso, A., Stunnenberg, H. G., Martens, J. H. A., Carafa, V., & Altucci, L. (2021) · Epigenetics · doi:10.1080/15592294.2020.1827723 · Cited by 44
Morschhauser, F., Terriou, L., Coiffier, B., Bachy, E., Varga, A., Kloos, I., Lelièvre, H., Sarry, A.-L., Depil, S., & Ribrag, V. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0206-x · Cited by 44
Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases
Ahmadi, M., Gharibi, T., Dolati, S., Rostamzadeh, D., Aslani, S., Baradaran, B., Younesi, V., & Yousefi, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.072 · Cited by 44
Bukowinski, A., Chang, B. H., Reid, J. M., Liu, X., Minard, C. G., Trepel, J. B., Lee, M., Fox, E., & Weigel, B. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28892 · Cited by 44
Li, K., Gao, S., Ma, L., Sun, Y., Peng, Z.-Y., Wu, J., Du, N., Ren, H., Tang, S., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.731561 · Cited by 44
Targetable Brg1‐CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking
Li, N., Liu, H., Xue, Y., Xu, Z., Miao, X., Guo, Y., Li, Z., Fan, Z., & Xu, Y. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216592 · Cited by 44
Mahato, R. K., Bhattacharya, S., Khullar, N., Sidhu, I. S., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.003 · Cited by 44
Zhang, P., Rausch, C., Hastert, F. D., Boneva, B., Filatova, A., Patil, S. J., Nuber, U. A., Gao, Y., Zhao, X., & Cardoso, M. C. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx281 · Cited by 43
Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
Cheng, C. L., Tsang, F. H., Wei, L., Chen, M., Chin, D. W., Shen, J., Law, C., Lee, D., Wong, C. C., Wong, C., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02405-6 · Cited by 43
Fedoriw, A., Shi, L., O’Brien, S. W., Smitheman, K. N., Wang, Y., Hou, J., Sherk, C. S., Rajapurkar, S., Laraio, J., Williams, L. J., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0614 · Cited by 43
Su, Y., Li, Y., Guo, R., Zhao, J., Chi, W., Lai, H., Wang, J., Wang, Z., Li, L., Sang, Y., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00356-z · Cited by 43
Self-citationPham, T. H., Lee, G. H., Jin, S. W., Lee, S. Y., Han, E. H., Kim, N. D., & Jeong, H. G. (2022) · Phytotherapy Research · doi:10.1002/ptr.7526 · Cited by 43
Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 43
Chen, C.-J., Huang, J., Huang, J., Deng, J., Shangguan, X., Chen, A.-Z., Chen, L., & Wu, W.-H. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2170521 · Cited by 43
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Ma, Z., Bolinger, A. A., Chen, H., & Zhou, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00948 · Cited by 43
Qin, S., Xie, B., Wang, Q., Yang, R., Sun, J., Hu, C., Liu, S., Tao, Y., & Xiao, D. (2024) · MedComm · doi:10.1002/mco2.551 · Cited by 43
Self-citationWang, J., Zeng, Z., Sun, J., Chen, Y., & Gao, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105869 · Cited by 42
Hess, L., Moos, V., Lauber, A. A., Reiter, W., Schuster, M. K., Hartl, N., Lackner, D. H., Boenke, T., Koren, A., Guzzardo, P. M., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010376 · Cited by 42
Dawson, M. A., Borthakur, G. M., Huntly, B. J. P., Karadimitris, A., Alegre, A. M., Chaidos, A., Vogl, D. T., Pollyea, D. A., Davies, F. E., Morgan, G. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1284 · Cited by 42
Fang, T., Jiao, Z., You, Y., Cao, J., Wang, C., Liu, J., & Zhao, W. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115489 · Cited by 42
Wang, Y., Hu, P., Wang, F., Xi, S., Wu, S., Sun, L.-Z., Du, Y., Zheng, J., Yang, H., Tang, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05895-w · Cited by 42
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Shen, L., Wang, B., Wang, S., Ji, S., Fu, M., Wang, S.-W., Hou, W., Dai, X., & Liu, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02133 · Cited by 42
Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications
Dreier, M. R., Walia, J., & de la Serna, I. L. (2024) · Epigenomes · doi:10.3390/epigenomes8010007 · Cited by 42
In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR/Cas9 nuclease system
Narayanan, A., Hill-Terán, G., Moro, A., Ristori, E., Kasper, D. M., Roden, C., Lü, J., & Nicoli, S. (2016) · Scientific Reports · doi:10.1038/srep32386 · Cited by 41
Navarro-Sánchez, L., Águeda-Gómez, B., Aparicio, S. F., & Pérez‐Tur, J. (2018) · Cells · doi:10.3390/cells7100150 · Cited by 41
Niinuma, T., Kitajima, H., Kai, M., Yamamoto, E., Yorozu, A., Ishiguro, K., Sasaki, H., Sudo, G., Toyota, M., Hatahira, T., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0668-3 · Cited by 41
Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
Moertl, S., Payer, S., Kell, R., Winkler, K., Anastasov, N., & Atkinson, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133259 · Cited by 41
Liu, Y., Yu, Y., Zhang, J., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116868 · Cited by 41
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
Albany, C., Fazal, Z., Singh, R., Bikorimana, E., Adra, N., Hanna, N. H., Einhorn, L. H., Perkins, S. M., Sandusky, G. E., Christensen, B. C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3583 · Cited by 41
The metabolic-epigenetic nexus in type 2 diabetes mellitus
Davison, G. W., Irwin, R. E., & Walsh, C. P. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.025 · Cited by 41
Vitamin C Inhibits the Metabolic Changes Induced by Tet1 Insufficiency Under High Fat Diet Stress
Yuan, Y., Liu, C., Chen, X., Sun, Y., Xiong, M., Fan, Y., Petersen, R. B., Chen, H., Huang, K., & Zheng, L. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100417 · Cited by 41
Novel role of UHRF1 in the epigenetic repression of the latent HIV-1
Verdikt, R., Bendoumou, M., Bouchat, S., Nestola, L., Pasternak, A. O., Darcis, G., Avettand-Fènoël, V., Vanhulle, C., Aït-Ammar, A., Santangelo, M., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103985 · Cited by 41
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Kurata, K., Samur, M., Liow, P., Wen, K., Yamamoto, L., Liu, J., Morelli, E., Gullà, A., Tai, Y., Qi, J., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3668 · Cited by 41
Iyer, S. P., Huen, A., Ai, W. Z., Jagadeesh, D., Lechowicz, M. J., Okada, C. Y., Feldman, T. A., Ghione, P., Alderuccio, J. P., Champion, R., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.281875 · Cited by 41
Shen, H., Ma, W., Hu, Y., Liu, Y., Song, Y., Fu, L., & Qin, Z. (2024) · Theranostics · doi:10.7150/thno.97320 · Cited by 41
Regulation of T cell differentiation and function by epigenetic modification enzymes
Liu, H., Li, P., Wei, Z., Zhang, C., Xia, M., Du, Q., Chen, Y., Liu, N., Li, H., & Yang, X. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00731-w · Cited by 40
Wang, Y., Li, J., Han, X., Wang, N., Song, C., Wang, R., & Chang, J. (2019) · Journal of Molecular Recognition · doi:10.1002/jmr.2800 · Cited by 40
Zhao, B. Q., Liang, Q., Ren, H., Zhang, X., Wu, Y. J., Zhang, K., Ma, L., Zheng, Y., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112161 · Cited by 40
Martin, P., Bartlett, N. L., Chávez, J. C., Reagan, J. L., Smith, S. M., LaCasce, A. S., Jones, J. S., Drew, J. B., Wu, C., Mulvey, E. C., et al. (2021) · Blood · doi:10.1182/blood.2021011679 · Cited by 40
Li, X., Yao, Y., Wu, F., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01258-8 · Cited by 40
Mammalian DNA N6-methyladenosine: Challenges and new insights
Feng, X., & He, C. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.005 · Cited by 40
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
Luke, J. J., Fakih, M., Schneider, C. J., Chiorean, E. G., Bendell, J. C., Kristeleit, R. S., Kurzrock, R., Blagden, S. P., Braña, I., Goff, L. W., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02267-1 · Cited by 40
O’Brien, S. W., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R. G., Mohammad, H. P., & Fedoriw, A. (2023) · BMC Cancer · doi:10.1186/s12885-023-11260-z · Cited by 40
Bazinet, A., Garcia‐Manero, G., Short, N. J., Alvarado, Y., Bataller, Á., Abuasab, T., Islam, R., Montalbano, K. S., Issa, G. C., Maiti, A., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00033-4 · Cited by 40
Lynch, D., Washam, J. B., & Newby, L. K. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0078 · Cited by 39
The essential role of acetyllysine binding by the YEATS domain in transcriptional regulation
Andrews, F. H., Shanle, E. K., Strahl, B. D., & Kutateladze, T. G. (2016) · Transcription · doi:10.1080/21541264.2015.1125987 · Cited by 39
Pippa, S., Mannironi, C., Licursi, V., Bombardi, L., Colotti, G., Cundari, E., Mollica, A., Coluccia, A., Naccarato, V., Regina, G. L., et al. (2019) · Molecules · doi:10.3390/molecules24091739 · Cited by 39
Shishikura, D., Kataoka, Y., Honda, S., Takata, K., Kim, S. W., Andrews, J., Psaltis, P. J., Sweeney, M., Kulikowski, E., Johansson, J., et al. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0298-8 · Cited by 39
Moreno, V., Sepúlveda-Sánchez, J. M., Reardon, D. A., Pérez‐Núñez, Á., González, P., Hanna, B., Filvaroff, E. H., Aronchik, I., Chang, H., Amoroso, B., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac263 · Cited by 39
Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02628-x · Cited by 39
Amatori, S., Bagaloni, I., Viti, D., & Fanelli, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.016 · Cited by 38
Sharma, A. R., Vatapalli, R. J., Abdelfatah, E., McMahon, K. W., Kerner, Z. J., Guzzetta, A. A., Singh, J., Zahnow, C. A., Baylin, S. B., Yerram, S. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176139 · Cited by 38
Paroni, G., Bolis, M., Zanetti, A., Ubezio, P., Helin, K., Staller, P., Gerlach, L. O., Fratelli, M., Neve, R. M., Terao, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0620-6 · Cited by 38
Chang, L., Campbell, J. C., Raji, I. O., Guduru, S. K. R., Kandel, P., Nguyen, M., Liu, S., Tran, K., Venugopal, N. K., Taylor, B. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80588-4 · Cited by 38
Self-citationRuan, J., Zain, J. M., Palmer, B. A., Jovanovic, B. D., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009767 · Cited by 38
Yong, W. P., Goh, B. C., Soo, R. A., Toh, H. C., Ethirajulu, K., Wood, J. M., Novotny‐Diermayr, V., Lee, S. C., Yeo, W. L., Chan, D., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq784 · Cited by 37
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A
Horton, J. R., Woodcock, C. B., Chen, Q., Liu, X., Zhang, X., Shanks, J. R., Rai, G., Mott, B. T., Jansen, D. J., Kales, S. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01219 · Cited by 37
Wieduwilt, M. J., Pawłowska, N., Thomas, S., Olin, R. L., Logan, A. C., Damon, L. E., Martin, T., Kang, M., Sayre, P. H., Boyer, W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0171 · Cited by 37
Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2
Kim, M. Y., Na, I., Kim, J. S., Son, S. H., Choi, S., Lee, S. E., Kim, J.-H., Jang, K., Alterovitz, G., Chen, Y., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav9810 · Cited by 37
Clegg, M. A., Bamborough, P., Chung, C., Craggs, P. D., Gordon, L. J., Grandi, P., Leveridge, M. V., Lindon, M. J., Liwicki, G. M., Michon, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00075 · Cited by 37
Moreno–Yruela, C., Bæk, M., Vrsanova, A.-E., Schulte, C., Maric, H. M., & Olsen, C. A. (2021) · Nature Communications · doi:10.1038/s41467-020-20250-9 · Cited by 37
Roboz, G. J., Desai, P. M., Lee, S., Ritchie, E. K., Winer, E. S., DeMario, M., Brennan, B. J., Nüesch, E., Chesné, E., Brennan, L., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1881509 · Cited by 37
Liu, X., Xu, B., Yang, J., He, L., Zhang, Z., Cheng, X. L., Yu, H., Liu, X., Jin, T. Y., Peng, Y., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.05.022 · Cited by 37
Self-citationWang, X., Wang, D., Ding, N., Mi, L., Yu, H., Wu, M., Feng, F., Hu, L., Zhang, Y., Zhong, C., et al. (2021) · Cancers · doi:10.3390/cancers13174249 · Cited by 37
Dickinson, M. J., Briones, J., Herrera, A. F., González-Barca, E. M., Ghosh, N., Córdoba, R., Rutherford, S. C., Bournazou, E., Labriola–Tompkins, E., Franjkovic, I., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004619 · Cited by 37
Xiao, P., Meng, Q., Liu, Q., Lang, Q., Yin, Z., Li, G., Li, Z., Xu, Y., Yu, Z., Geng, Q., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216075 · Cited by 37
Lubecka, K., Kaufman‐Szymczyk, A., Stefañska, B., Cebula‐Obrzut, B., Smolewski, P., & Fabianowska‐Majewska, K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.021 · Cited by 36
Yu, C.-C., Pan, S., Chao, S.-W., Liu, S., Hsu, J., Yang, Y. S. H., Li, T., Huang, W., & Guh, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.001 · Cited by 36
Self-citationXu, J., Wang, Q., Leung, E. L., Li, Y., Fan, X., Wu, Q., Yao, X., & Liu, L. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0694-8 · Cited by 36
Guan, Y., Hasipek, M., Jiang, D., Tiwari, A. D., Grabowski, D. R., Pagliuca, S., Kongkiatkamon, S., Patel, B., Singh, S., Parker, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci149856 · Cited by 36
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
Karasic, T. B., Brown, T. J., Schneider, C. J., Teitelbaum, U. R., Reiss, K. A., Mitchell, T. C., Massa, R. C., O’Hara, M. H., Dicicco, L., Garcia-Marcano, L., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac078 · Cited by 36
EP300 facilitates human trophoblast stem cell differentiation
van Voorden, J., Keijser, R., Veenboer, G. J. M., Cardozo, S. L., Diek, D., Vlaardingerbroek, J. A., van Dijk, M., Ris‐Stalpers, C., van Pelt, A. M. M., & Afink, G. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217405120 · Cited by 36
Li, D., Peng, X., Hu, Z., Li, S., Chen, J., & Pan, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115982 · Cited by 36
Self-citationXu, D. C., Sas‐Nowosielska, H., Donahue, G., Huang, H., Pourshafie, N., Good, C. R., & Berger, S. L. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01696-6 · Cited by 36
Tian, Y., Zhang, M., Liu, L., Wang, Z.-C., Liu, B., Huang, Y., Wang, X., Ling, Y., Wang, F., Feng, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400744 · Cited by 36
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
Moreau, P., Facon, T. T. F., Touzeau, C., Benboubker, L., Delain, M., Badamo-Dotzis, J., Phelps, C. E., Doty, C., Smit, H., Fourneau, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1117611 · Cited by 35
Pan, H., Bilinovich, S. M., Kaur, P., Riehn, R. E., Wang, H., & Williams, D. C. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx548 · Cited by 35
Ikeda, M., Ohno, I., Ueno, H., Mitsunaga, S., Hashimoto, Y., Okusaka, T., Kondo, S., Sasaki, M., Sakamoto, Y., Takahashi, H., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0634-5 · Cited by 35
Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition
Giordano, A., Forte, G., Terracciano, S., Russo, A., Sala, M., Scala, M. C., Johansson, C., Oppermann, U. C. T., Riccio, R., Bruno, I., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00589 · Cited by 35
Kharenko, O. A., Patel, R. G., Calosing, C., & van der Horst, E. H. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00375-9 · Cited by 35
Screening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system
Li, S., Wu, H., & Chen, L. (2022) · Nature Protocols · doi:10.1038/s41596-022-00715-5 · Cited by 35
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase
Chandhasin, C., Dang, V., Perabo, F., Rosario, J. D., Chen, Y. K., Filvaroff, E. H., Stafford, J. A., & Clarke, M. F. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001514 · Cited by 35
Fenaux, P., Gobbi, M., Kropf, P. L., Issa, J. J., Roboz, G. J., Mayer, J., Krauter, J., Robak, T., Kantarjian, H. M., Novák, J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010179 · Cited by 35
Wells, A. C., Hioki, K. A., Angelou, C. C., Lynch, A. C., Liang, X., Ryan, D. J., Thesmar, I., Zhanybekova, S., Žuklys, S., Ullom, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40959-7 · Cited by 35
Garcia‐Manero, G., Podoltsev, N. A., Othus, M. K. D., Pagel, J. M., Radich, J. P., Fang, M., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M. R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02073-x · Cited by 35
Identification of ryuvidine as a KDM5A inhibitor
Mitsui, E., Yoshida, S., Shinoda, Y., Matsumori, Y., Tsujii, H., Tsuchida, M., Wada, S., Hasegawa, M., Ito, A., Mino, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46346-x · Cited by 34
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions
Lavacchi, D., Caliman, E., Rossi, G., Buttitta, E., Botteri, C., Fancelli, S., Pellegrini, E., Roviello, G., Pillozzi, S., & Antonuzzo, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108170 · Cited by 34
Caligiuri, M., Williams, G. L., Castro, J., Battalagine, L., Wilker, E., Yao, L., Schiller, S., Toms, A. V., Li, P., Pardo, E., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00949-7 · Cited by 34
Circulating exosomal microRNAs as biomarkers of lupus nephritis
Chen, F., Shi, B., Liu, W., Gong, J., Gao, J., Sun, Y., & Yang, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326836 · Cited by 34
Jiang, W., Hou, Q., Xu, H., Yang, K., Wang, X., Zhang, K., Zeng, Y., Li, W., Wang, B., Luo, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02104 · Cited by 34
Chen, H., Xin, W., Jiang, J., Shan, A., & Ma, J. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.133854 · Cited by 34
Jin, H., Chen, Y., Zhang, D., Lin, J., Huang, S., Wu, X., Deng, W., Huang, J., & Yao, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109902 · Cited by 34
Miyake, Y., Itoh, Y., Hatanaka, A., Suzuma, Y., SUZUKI, M. T., Kodama, H., Arai, Y., & Suzuki, T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.006 · Cited by 33
Zhang, W., Sviripa, V. M., Xie, Y., Yu, T., Haney, M. G., Blackburn, J. S., Adeniran, C. A., Zhan, C., Watt, D. S., & Liu, C. (2020) · iScience · doi:10.1016/j.isci.2020.101795 · Cited by 33
Parag‐Sharma, K., Tasoulas, J., Musicant, A. M., Filho, C., Zhu, Z., Twomey, C., Liu, P., CASTILHO, R. M., & Amelio, A. L. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105166 · Cited by 33
Mason, L. D., Chava, S., Reddi, K. K., & Gupta, R. (2021) · Cancers · doi:10.3390/cancers13215516 · Cited by 33
Saunders, M. P., Graham, J., Cunningham, D., Plummer, R., Church, D. N., Kerr, R. S., Cook, S., Zheng, S. S., Thangue, N. B. L., & Kerr, D. J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100594 · Cited by 33
Li, Y., Xie, Z., Luo, X., Wang, X., Wang, Y., Guo, M., Zhou, Z., Sun, R., Hua, D., Luo, A., et al. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200735 · Cited by 33
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors
Ye, C., Jiang, N., Zheng, J., Zhang, S., Zhang, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189066 · Cited by 33
He, T., Cheng, C., Qiao, Y., Cho, H., YOUNG, E. A., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322563121 · Cited by 33
The SWI/SNF ATP-dependent chromatin remodeling complex in cell lineage priming and early development
Saha, D., Animireddy, S., & Bartholomew, B. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230416 · Cited by 33
Harnessing noncanonical crRNA for highly efficient genome editing
Xun, G., Zhu, Z., Singh, N., Lu, J., Jain, P., & Zhao, H. (2024) · Nature Communications · doi:10.1038/s41467-024-48012-x · Cited by 33
Dabiri, Y., Gama-Brambila, R. A., Taškova, K., Herold, K., Reuter, S., Adjaye, J., Utikal, J. S., Mrowka, R., Wang, J., Andrade-Navarro, M. A., et al. (2019) · iScience · doi:10.1016/j.isci.2019.01.012 · Cited by 32
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
Munakata, W., Shirasugi, Y., Tobinai, K., Onizuka, M., Makita, S., Suzuki, R., Maruyama, D., Kawai, H., Izutsu, K., Nakanishi, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14822 · Cited by 32
Wu, P.-F., Han, Q.-Q., Chen, F.-F., Shen, T.-T., Li, Y.-H., Cao, Y., Chen, J.-G., & Wang, F. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100390 · Cited by 32
Weber, J. S., Levinson, B. A., Laino, A. S., Pavlick, A. C., & Woods, D. M. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000818 · Cited by 32
Song, N., Guan, X., Zhang, S., Wang, Y., Wang, X., Lu, Z., Chong, D., Wang, Y., Yu, R., Yu, W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06018-1 · Cited by 32
Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions
Brückmann, N. H., Pedersen, C. B., Ditzel, H. J., & Gjerstorff, M. F. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0477 · Cited by 31
Lim, B., Murthy, R. K., Lee, J., Jackson, S. A., Iwase, T., Davis, D. W., Willey, J. S., Wu, J., Shen, Y., Tripathy, D., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0473-y · Cited by 31
Li, X., Wu, Y., Tian, G., Jiang, Y., Liu, Z., Meng, X., Bao, X., Feng, L., Sun, H., Deng, H., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02738 · Cited by 31
Self-citationKim, J. K., Kan, G., Mao, Y., Wu, Z., Tan, X., He, H., & Lee, C. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12607 · Cited by 31
Cited by
Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review)
Saliev, T., & Singh, P. (2025) · Biomedical Reports · doi:10.3892/br.2025.1974 · Cited by 14
Metadata
- Authors
- Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., Xiao, X., & Li, D.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-11-26
- Volume
- 9
- Issue
- 1
- Pages
- 332-332
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4404726166
- Cited by
- 339
- References
- 1,077
- FWCI
- 39.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.